The stock of Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) is a huge mover today! About 100,862 shares traded hands. Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) has declined 21.83% since April 28, 2016 and is downtrending. It has underperformed by 27.75% the S&P500.
The move comes after 8 months positive chart setup for the $16.37M company. It was reported on Dec, 1 by Barchart.com. We have $4.13 PT which if reached, will make NASDAQ:CYCC worth $654,800 more.
Analysts await Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) to report earnings on March, 23. They expect $-0.89 EPS, up 25.83% or $0.31 from last year’s $-1.2 per share. After $-0.86 actual EPS reported by Cyclacel Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 3.49% negative EPS growth.
According to Zacks Investment Research, “CYCLACEL is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Three orally-available Cyclacel drugs are in clinical development. Sapacitabine, a cell cycle modulating nucleoside analog, is in Phase 2 studies for the treatment of acute myeloid leukemia in the elderly, myelodysplastic syndromes and cutaneous T-cell lymphoma. Seliciclib (CYC202 or R-roscovitine), a CDK inhibitor, is in Phase 2 for the treatment of lung cancer and nasopharyngeal cancer.”
Insitutional Activity: The institutional sentiment decreased to 0 in 2016 Q2. Its down 0.09, from 0.09 in 2016Q1. The ratio worsened, as 23 funds sold all Cyclacel Pharmaceuticals Inc shares owned while 0 reduced positions. 2 funds bought stakes while 0 increased positions. They now own 13,631 shares or 99.80% less from 6.70 million shares in 2016Q1.
Baker Bros Limited Partnership owns 13,253 shares or 0% of their US portfolio. Tower Capital Limited Liability Co (Trc) accumulated 0% or 378 shares.
More notable recent Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) news were published by: Marketwatch.com which released: “Plus the latest data from Realtor.com on 21 home markets across the US” on September 11, 2009, also Streetinsider.com with their article: “Cyclacel Pharma (CYCC) Announces Presentation of Encouraging Preclinical …” published on December 01, 2016, Investorplace.com published: “Cyclacel Pharmaceuticals Inc (CYCC): Don’t Believe the Hype” on August 22, 2016. More interesting news about Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) were released by: Seekingalpha.com and their article: “Cyclacel Pharmaceuticals, Inc.’s (CYCC) CEO Spiro Rombotis on Q2 2016 Results …” published on August 10, 2016 as well as Quotes.Wsj.com‘s news article titled: “News Cyclacel Pharmaceuticals Inc.CYCC” with publication date: February 11, 2011.
CYCC Company Profile
Cyclacel Pharmaceuticals, Inc., incorporated on January 5, 1996, operates in the field of cell cycle biology. The Firm has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors. The Company’s family of anticancer drugs acts on the cell cycle.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.